Q BioMed Inc. (QBIO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -2.05 Million USD | 91.81% |
| 2021 | -8.74 Million USD | 36.56% |
| 2020 | -13.78 Million USD | -17.45% |
| 2019 | -11.74 Million USD | -26.64% |
| 2018 | -9.27 Million USD | 36.25% |
| 2017 | -14.54 Million USD | -102.77% |
| 2016 | -7.17 Million USD | -559.99% |
| 2015 | -1.08 Million USD | -2755.76% |
| 2014 | -38.05 Thousand USD | -7510.0% |
| 2013 | -500.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 100.0% |
| 2023 Q1 | -826.41 Thousand USD | -135.89% |
| 2022 Q1 | -3.41 Million USD | -64.86% |
| 2022 Q3 | -809.5 Thousand USD | 57.22% |
| 2022 Q4 | 2.3 Million USD | 384.43% |
| 2022 FY | -716.09 Thousand USD | 91.81% |
| 2022 Q2 | -1.89 Million USD | 44.54% |
| 2021 Q3 | -1.78 Million USD | 6.33% |
| 2021 Q1 | -2.47 Million USD | 27.84% |
| 2021 Q4 | -2.06 Million USD | -15.8% |
| 2021 Q2 | -1.9 Million USD | 22.9% |
| 2021 FY | -8.74 Million USD | 36.56% |
| 2020 FY | -13.78 Million USD | -17.45% |
| 2020 Q4 | -3.43 Million USD | -51.92% |
| 2020 Q1 | -5.94 Million USD | -140.58% |
| 2020 Q2 | -1.86 Million USD | 68.66% |
| 2020 Q3 | -2.25 Million USD | -21.23% |
| 2019 Q2 | -2.88 Million USD | -21.6% |
| 2019 Q1 | -2.37 Million USD | -13.19% |
| 2019 FY | -11.74 Million USD | -26.64% |
| 2019 Q4 | -2.46 Million USD | 3.02% |
| 2019 Q3 | -2.54 Million USD | 11.82% |
| 2018 Q3 | -2.98 Million USD | -48.33% |
| 2018 Q4 | -2.09 Million USD | 29.72% |
| 2018 FY | -9.27 Million USD | 36.25% |
| 2018 Q1 | -2.17 Million USD | 47.91% |
| 2018 Q2 | -2.01 Million USD | 7.42% |
| 2017 Q4 | -4.17 Million USD | -4.84% |
| 2017 FY | -14.54 Million USD | -102.77% |
| 2017 Q3 | -3.98 Million USD | -39.73% |
| 2017 Q2 | -2.84 Million USD | 19.43% |
| 2017 Q1 | -3.53 Million USD | -50.03% |
| 2016 Q2 | -783.95 Thousand USD | 66.12% |
| 2016 Q1 | -2.31 Million USD | -122.21% |
| 2016 FY | -7.17 Million USD | -559.99% |
| 2016 Q4 | -2.35 Million USD | -37.37% |
| 2016 Q3 | -1.71 Million USD | -118.9% |
| 2015 Q3 | -33.2 Thousand USD | -774.2% |
| 2015 Q2 | -3798.00 USD | 53.59% |
| 2015 Q1 | -8184.00 USD | 58.02% |
| 2015 FY | -1.08 Million USD | -2755.76% |
| 2015 Q4 | -1.04 Million USD | -3036.66% |
| 2014 FY | -38.05 Thousand USD | -7510.0% |
| 2014 Q4 | -19.49 Thousand USD | -218.62% |
| 2014 Q3 | -6118.00 USD | -33.9% |
| 2014 Q1 | -7869.00 USD | 0.0% |
| 2014 Q2 | -4569.00 USD | 41.94% |
| 2013 FY | -500.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -53.665% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 70.612% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 103.873% |
| Nascent Biotech, Inc. | -2.08 Million USD | 1.705% |
| Rebus Holdings, Inc. | -1.02 Million USD | -101.186% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 103.151% |
| Qrons Inc. | -789.34 Thousand USD | -159.973% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -224.489% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 96.722% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -393.91% |
| Skye Bioscience, Inc. | -37.64 Million USD | 94.549% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.263% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 68.795% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -650.577% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.418% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 29.052% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -12.72% |
| Mesoblast Limited | -87.95 Million USD | 97.667% |
| Marizyme, Inc. | -65.34 Million USD | 96.86% |
| Genus plc | 7.9 Million USD | 125.976% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 81.159% |
| Pharming Group N.V. | -10.54 Million USD | 80.545% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 5.425% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 44.691% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 76.797% |
| ContraFect Corporation | -65.15 Million USD | 96.85% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 58.001% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -18.793% |
| IMV Inc. | -36.48 Million USD | 94.376% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 74.539% |
| MultiCell Technologies, Inc. | -380.07 USD | -539825.014% |
| ONE Bio Corp. | 8.67 Million USD | 123.651% |
| Accustem Sciences Inc. | -3.74 Million USD | 45.225% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 96.03% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -61.948% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 45.028% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 13.809% |
| Biomind Labs Inc. | -1.21 Million USD | -68.991% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 96.564% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 33.841% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 74.034% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -5.276% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -13602.544% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 87.071% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 64.724% |
| GB Sciences, Inc. | -1.36 Million USD | -50.703% |
| Alpha Cognition Inc. | -13.77 Million USD | 85.1% |
| HST Global, Inc. | -146.21 Thousand USD | -1303.524% |
| CSL Limited | 2.64 Billion USD | 100.078% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -16.944% |
| Halberd Corporation | -79.67 Thousand USD | -2475.547% |
| Enzolytics Inc. | -2.17 Million USD | 5.73% |
| Agentix Corp. | -1.37 Million USD | -49.329% |
| Resverlogix Corp. | -3.61 Million USD | 43.155% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 35.295% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.305% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2193.972% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 129.635% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 48.349% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 32.188% |
| AVAX Technologies, Inc. | -6.41 Million USD | 68.004% |
| Zenith Capital Corp. | -10.59 Million USD | 80.633% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.851% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -8729.244% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 50.504% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -3295.222% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -2.343% |
| Kadimastem Ltd | -3.3 Million USD | 37.954% |
| Helix BioMedix, Inc. | -1.05 Million USD | -94.316% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 46.266% |
| BioStem Technologies, Inc. | -8.48 Million USD | 75.809% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -364.938% |
| LadRx Corporation | 400.44 Thousand USD | 612.456% |
| Cell Source, Inc. | -5.32 Million USD | 61.436% |
| Regen BioPharma, Inc. | 1.02 Million USD | 300.496% |
| Regen BioPharma, Inc. | 1.02 Million USD | 300.496% |
| NovAccess Global Inc. | -4.76 Million USD | 56.972% |
| Affymax, Inc. | -14.42 Million USD | 85.773% |
| Itoco Inc. | -1.86 Million USD | -9.797% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 53.808% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -22.953% |
| Mobile Lads Corp. | -2.26 Million USD | 9.331% |
| CytoDyn Inc. | -49.84 Million USD | 95.883% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2496.501% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -799.54% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -117.953% |
| SYBLEU INC | -180.3 Thousand USD | -1038.129% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -27.243% |
| International Stem Cell Corporation | -131 Thousand USD | -1466.483% |
| Bioxytran, Inc. | -4.28 Million USD | 52.054% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -3681.127% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 18.898% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 95.731% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 2.928% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -162.79% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 35.224% |
| Neutra Corp. | -233.46 Thousand USD | -778.972% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 89.887% |
| PureTech Health plc | -65.69 Million USD | 96.876% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 90.351% |
| IXICO plc | -1.17 Million USD | -74.201% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 79.328% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 96.408% |
| CSL Limited | 2.64 Billion USD | 100.078% |
| Cellectis S.A. | -103.17 Million USD | 98.011% |